Dexamethasone erythrocyte-encapsulated - EryDel

Drug Profile

Dexamethasone erythrocyte-encapsulated - EryDel

Alternative Names: Dexa 21-P – EryDel; Ery-Dex

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator EryDel
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ataxia telangiectasia; Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ataxia telangiectasia
  • Phase I Duchenne muscular dystrophy
  • Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Ulcerative colitis

Most Recent Events

  • 06 Mar 2017 Phase-III clinical trials in Ataxia telangiectasia (In children, In adolescents, In adults, In the elderly) in Tunisia, India, Australia, Israel, USA (IV)
  • 03 Feb 2016 EryDel completes a phase II trial in Ataxia telangiectasia in Italy before February 2016
  • 03 Aug 2015 Phase II development for Ataxia telangiectasia is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top